Instruction 1(b)

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Broadfe (Last) 3545 JOI (Street)	3545 JOHN HOPKINS COURT, SUITE 250						Issuer Name and Ticker or Trading Symbol aTYR PHARMA INC [LIFE] Date of Earliest Transaction (Month/Day/Year) 02/03/2022 4. If Amendment, Date of Original Filed (Month/Day/Year)								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) Chief Financial Officer 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting						
(City)	(S		(Zip)			Person															
			le I - Non-							Dis	1										
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						Execution Da		Date,	Code						5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) o (D)	r Pri	се					(1115ti. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Yo		ransac ode (In				6. Date Exercis Expiration Date (Month/Day/Yea		•	7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Owners Form: Direct (or Indir (I) (Inst	Ownership	Beneficial Ownership ct (Instr. 4)		
				c	ode	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amou or Numb of Share	oer							
Employee Stock Option (right to buy)	\$5.52	02/03/2022			A		30,000		(1)	(02/03/2032	Common Stock	30,0	00	\$0.00	30,000)	D			
Restricted Stock Units	(2)	02/03/2022			A		15,000		(3)		(3)	Common Stock	15,0	00	\$0.00	15,000)	D			

Explanation of Responses:

- 1. The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 3, 2022, such that this option will be fully exercisable on February 3, 2026. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.
- 2. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
- 3. The RSUs are scheduled to vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. This grant is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer

Remarks:

Nancy E. Denyes, attorney-in-

02/07/2022

fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.